Yong-Seok Kim

Yong-Seok Kim

Auto-generated profile, based on publicly available information

Yong-Seok Kim

Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
HWHye Sung Won
Hye Sung Won
JAJuneyoung Ahn
Juneyoung Ahn
YKYongseon Kim
Yongseon Kim
JKJin Sung Kim
Jin Sung Kim
JSJeong-Yoon Song
Jeong-Yoon Song
YKYong-Seok Kim
Yong-Seok Kim
Background: There is an increasing interest in HER2-low breast cancer with promising data from clinical trials using novel anti-HER2 antibody–drug conjugates. We explored the differences in clinicopathological characteristics and survival outcomes between HER2-low and HER2-IHC 0 breast cancer. Methods: Using nationwide data from the Korean Breast Cancer Registry between 2006 and 2011, 30,491 patients with stages I to III breast cancer were included in the analysis: 9,506 (31.2%) in the HER2-low group and 20,985 (68.8%) in the HER2-IHC 0 group. Kaplan–Meier and Cox proportional hazards regression survival analysis were used to compare breast cancer-specific survival between the two groups. Results: HER2-low breast cancer was more frequent in patients with hormone receptor-positive breast cancer than in those with triple-negative breast cancer. In patients with hormone receptor-positive breast cancer, HER2-low breast cancer was associated with fewer T4 tumors, higher histological grade, and a negative lymphatic invasion. In patients with triple-negative breast cancer, HER2-low breast cancer was associated with a high lymph node ratio and positive lymphatic invasion. HER2-low breast cancer was significantly associated with a lower Ki-67 labeling index. No significant difference was observed in overall survival between the two groups. HER2-low breast cancer showed significantly better breast cancer-specific survival than HER2-IHC 0 breast cancer, regardless of the hormone receptor status. In multivariate analysis, the impact of low HER2 expression on breast cancer-specific survival was significant only in triple-negative breast cancer (HRs, 0.68; 95% CI, 0.49–0.93; P = 0.019). Conclusions: These findings suggest that the biology and clinical impact of low HER2 expression can differ according to the hormone receptor status and support the need for further investigation on the understanding of the biology of HER2-low breast cancer.

16 August 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YKYong-Seok Kim
Yong-Seok Kim
WPWoo-Chan Park
Woo-Chan Park
Central and lateral lymph node metastases are quite common in patients with papillary thyroid carcinoma, and the predictors for those metastases have been well studied. Right upper paraesophageal lymph node metastasis has rarely been studied. The aim of this study was to identify the clinicopathological characteristics that may be risk factors for right upper paraesophageal lymph node metastasis in patients with papillary thyroid carcinoma.

1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
YKYoung-Joon Kang
Young-Joon Kang
JBJongmin Baek
Jongmin Baek
YKYong-Seok Kim
Yong-Seok Kim
YJYe Won Jeon
Ye Won Jeon
TYTae-Kyung Yoo
Tae-Kyung Yoo
SOSe Jeong Oh
Se Jeong Oh
Kang YJ, et al. J Breast Cancer. 2021 Dec;24:e55. https://doi.org/10.4048/jbc.2021.24.e55

7 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYoung-Joon Kang
Young-Joon Kang
SOSe Jeong Oh
Se Jeong Oh
SBSoo Youn Bae
Soo Youn Bae
EKEun-Kyu Kim
Eun-Kyu Kim
YLYoung-Jin Lee
Young-Jin Lee
YKYong-Seok Kim
Yong-Seok Kim
The human epidermal growth factor receptor-2 (HER2) enriched subtype of breast cancer is associated with early recurrence, mostly within 5 years. However, anti-HER2 therapies have improved outcomes and their benefits persist in the long term. This study aimed to determine predictive factors for late survival in patients with HER2-positive breast cancer. We analyzed 20,672 patients with HER2-positive stage I–III breast cancer. The patients were divided into two groups based on a follow-up period of 60 months. The multivariate analysis of factors associated with poor overall survival included old age, advanced pathologic tumor size stage (pT), advanced pathologic regional lymph node stage (pN), high histological grade, presence of lymphatic and vascular invasion, and HR-negative status within 60 months. In the breast cancer-specific survival (BCSS) of the > 60 months follow-up group, the hazard ratios (HRa) based on pN-negative were 3.038, 3.722, and 4.877 in pN1 (p = 0.001), pN2 (p < 0.001), and pN3 (p < 0.001), respectively. Only pT4 level was statistically significant in the pT group (HRa, 4.528; p = 0.007). Age (HRa, 1.045, p < 0.001) and hormone receptor-positive status (HRa, 1.705, p = 0.022) were also associated to worse BCSS. Although lymphatic invasion was not significantly associated with BCSS, there was a tendency toward a relationship (p = 0.079) with worse BCSS. In HER2-positive breast cancer patients, node status had a more significant relationship with long-term prognosis than T stage. Patients with HER2-positive breast cancer who have T4 or node-positive should be considered for clinical observation and education beyond 5 years.

5 August 2014 in BMC Surgery
Verified
Journal Article
Open access
PDF file
YKYong-Seok Kim
Yong-Seok Kim
KJKyu-Hwa Joo
Kyu-Hwa Joo
SPSun Cheol Park
Sun Cheol Park
KKKee-Hwan Kim
Kee-Hwan Kim
CAChang-hyeok An
Chang-hyeok An
JKJeong Soo Kim
Jeong Soo Kim
Thyroid carcinoma in young women is rapidly increasing, and cosmesis plays an important role in thyroid operations. Various endoscopic thyroid surgery approaches have been performed, and their application has recently been extended. We performed endoscopic thyroid surgeries via a breast approach since 1999. Herein, we evaluate the safety of this approach and identify the outcomes for differentiated thyroid carcinoma.

6 September 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
YJYe Won Jeon
Ye Won Jeon
SYSun Hyong You
Sun Hyong You
JLJong Eun Lee
Jong Eun Lee
HYHyun Jo Youn
Hyun Jo Youn
WLWoosung Lim
Woosung Lim
YKYong Seok Kim
Yong Seok Kim
The aim of this study was to investigate the therapeutic efficacy of adjuvant modalities for elderly Asian breast cancer patients using population-based data from the Korean Breast Cancer Registry database.